Hughes R, Ton H Y, Langley P, Davies M, Hanid M A, Mellon P, Silk D B, Williams R
Artif Organs. 1979 Feb;3(1):23-6. doi: 10.1111/j.1525-1594.1979.tb03800.x.
Albumin-coated Amberlite XAD-7 has been previously shown to be blood compatible in in vitro hemoperfusion experiments whith human blood. In this study, the preliminary results are reported on single hemoperfusions with albumin-coated XAD-7 resin in four patients with acute liver failure. The mean platelet count was 116+/-SE 16.3% of the initial arterial value and the mean white cell count was 96+/-SE 6.5% of initial at the end of four hours of hemoperfusion. Removal of bilirubin, phenols and substances in the middle molecular weight range by the resin was demonstrated. These preliminary results suggest albumin-coated Amberlite XAD-7 resin to be blood compatible and capable of removing protein-bound and middle molecular weight substances from patients with acute liver failure. Further clinical evaluation of repeated resin hemoperfusion is required to determine whether this treatment will be beneficial to patient survival.
白蛋白包被的Amberlite XAD - 7先前已在用人血进行的体外血液灌注实验中显示出具有血液相容性。在本研究中，报告了4例急性肝衰竭患者单次使用白蛋白包被的XAD - 7树脂进行血液灌注的初步结果。血液灌注4小时结束时，平均血小板计数为初始动脉值的116±标准误16.3%，平均白细胞计数为初始值的96±标准误6.5%。该树脂对胆红素、酚类和中等分子量范围内的物质有清除作用。这些初步结果表明白蛋白包被的Amberlite XAD - 7树脂具有血液相容性，并且能够从急性肝衰竭患者体内清除蛋白结合物和中等分子量物质。需要对重复树脂血液灌注进行进一步的临床评估，以确定这种治疗方法是否对患者生存有益。
